Status of Peptides as of May 22, 2020
Edwin Lee, M.D.
Status of Peptides as of May 22, 2020
Although no harm or deaths have been reported due to peptides, the FDA issued a letter to Tailor Made Compounding to stop making certain peptides by April 23, 2020. The agency also prohibited the pharmacy from selling these peptides by May 15, 2020. The following peptides may no longer be compounded:
CJC1295/ Ipamorelin
BPC 157
LL-37
DSIP
Epitalon
Kisspeptin 10
ARA-290
MOTS-c
Dihexa
IGF-1
iRGD
Melanotan II
PNC-27
Aniracetam
Currently, other compounding pharmacies are still able to produce most of the peptides listed above.
The FDA will very likely send letters to other compounding pharmacies to stop the production of the banned peptides since these substances lack FDA approval, a monograph or inclusion on the 503A Bulk Drug Substance List.
SavePeptides.org is a grassroots organization formed to preserve the use of peptides by requesting/lobbying for an open public meeting with the FDA to nominate the banned peptides to the 503A Bulk Drug Substance List. This group also wants to develop/get a monograph on each peptide.
Dr. Edwin Lee is an endocrinologist, author and international speaker. Dr. Lee founded the Institute for Hormonal Balance, Orlando, FL in 2008, is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism, and has completed special training in Regenerative and Functional Medicine. Currently, he is the assistant professor of Internal Medicine at the University of Central Florida College of Medicine. Dr. Lee is co-founder of the Clinical Peptide Society and a member of the AMMG Conference Planning Committee.